# Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

> **NCT02760433** · PHASE3 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 368 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Olokizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02760433
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-25
- **Primary completion:** 2019-09-12
- **Final completion:** 2019-10-01
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760433, "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02760433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*